Novartis India Ltd

Novartis India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 27 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical company’s Mojo Score has improved to 34.0, reflecting a more balanced outlook amid mixed fundamentals and valuation concerns.

Novartis India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. The stock’s recent price action, combined with mixed readings from MACD, RSI, moving averages, and other momentum oscillators, suggests a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Novartis India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 24 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Novartis India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Novartis India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with the latest comprehensive analysis.

Novartis India Ltd commenced trading today with a significant gap up, opening 5.47% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start follows a series of gains over the past two days, cumulatively delivering a 22.82% return, outpacing the broader market and sector benchmarks.

Novartis India Ltd recorded a robust intraday rally on 20 Feb 2026, surging to a day’s high of Rs 977.95, marking a 17.76% increase from the previous close. The stock outperformed its sector and the broader market, reflecting strong trading momentum amid a generally subdued Sensex session.

Novartis India Ltd (Stock ID: 333626) commenced trading on 20 Feb 2026 with a significant gap up, opening 8.86% higher than its previous close. This robust start was accompanied by an intraday high surge of 17.76%, signalling strong positive momentum in the Pharmaceuticals & Biotechnology sector amid a broader market that showed muted performance.

Novartis India Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its valuation, financial trends, quality metrics, and technical indicators. The downgrade reflects concerns over the company’s expensive valuation relative to peers, deteriorating quarterly financial performance, and subdued market momentum despite some long-term growth signals.

Novartis India Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its current price attractiveness. Despite a recent uptick in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical averages and peer benchmarks, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Novartis India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with the latest insights into its performance and outlook.

Novartis India Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in technical indicators despite ongoing financial challenges. The upgrade, effective from 04 Feb 2026, is driven primarily by improvements in technical trends, while valuation and financial performance remain under pressure. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Novartis India Ltd has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend, accompanied by a 6.43% surge in its share price on 5 Feb 2026. Despite this positive price movement, key technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes that investors should carefully consider.

Novartis India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Novartis India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s technical landscape reveals a complex interplay of bullish and bearish signals across weekly and monthly timeframes, underscoring the challenges facing investors in the Pharmaceuticals & Biotechnology sector.